JP2022126152A - Supplement and pet feed containing the same - Google Patents

Abstract

To optimize enterobacterial balance to prevent the development of various diseases; and to reduce the usage of antibiotics to reduce the risk of generation of drug-resistant bacteria.SOLUTION: A supplement of synbiotics uses spore-forming lactic acid bacteria and butyric acid bacteria as probiotics and uses kestose to be a nutrition source of probiotic bacteria such as bifidobacteria as prebiotics.SELECTED DRAWING: Figure 1

Description

There is an application for exception to loss of novelty

TECHNICAL FIELD The present invention relates to a supplement that regulates the intestinal flora of humans and animals, and pet food containing the same.

Pets have a high prevalence of gastrointestinal diseases, and the main cause is an imbalance of intestinal bacteria. For example, if the intestinal pH becomes alkaline due to excessive intake of animal protein, which is a nutrient source for bad bacteria, bad bacteria that prefer alkalinity will proliferate, and good bacteria that prefer acidity and dislike alkalinity will decrease. Bad bacteria become dominant over good bacteria, and gastrointestinal diseases such as diarrhea are more likely to occur.

Gastrointestinal diseases such as those described above are treated with antibiotics, but antibiotics also act on good bacteria and reduce their numbers, resulting in an increase in the proportion of bad bacteria. and may disrupt the intestinal bacterial balance. In addition, continued use of antibiotics strengthens the resistance of pathogenic bacteria to drugs, leading to the development of drug-resistant bacteria that are resistant to antibiotic treatment. Since drug-resistant bacteria infect not only animals but also humans, the impact is immeasurable.

Therefore, in order to prevent digestive disorders, many supplement products are provided to balance intestinal bacteria. For example, those that use probiotics, which are live microorganisms that improve the balance of the intestinal flora and have a beneficial effect on the host, and those that reach the intestine without being degraded or absorbed along the way after being taken orally. Some use prebiotics that improve the balance of intestinal flora by serving as a nutrient source for beneficial bacteria and helping the growth of beneficial bacteria (see, for example, Patent Document 1).

JP 2004-357505 A

However, there are some probiotics that are ineffective because dead bacteria are used as probiotics, or most of them are killed by digestive juices such as gastric acid and bile after ingestion before they reach the intestines. In addition, either prebiotics or prebiotics alone are less effective and do not sufficiently contribute to improving the balance of intestinal bacteria.

The present invention provides a supplement that can prevent the onset of various diseases by adjusting the balance of intestinal bacteria when ingested on a regular basis and reduce the risk of developing drug-resistant bacteria by reducing the use of antibiotics. The purpose is to provide a compounded pet food.

The invention according to claim 1 provides a supplement characterized by containing spore-bearing lactic acid bacteria, butyric acid bacteria, and kestose, and regulating intestinal flora.

The invention according to claim ₂ provides the supplement according to claim 1, wherein vitamin B2 and vitamin E are blended.

The invention according to claim 3 provides a pet food, characterized in that the supplement according to claim 1 or 2 is blended.

By orally ingesting the supplements according to claims 1 to 3 of the present invention and the pet food containing them, it is possible to improve health by regulating intestinal flora. _In addition, the combination of vitamin B2 and vitamin E, which have antioxidant effects, can be expected to have the effect of improving various diseases such as skin diseases.

1 is a graph showing the rate of improvement in the total score on the 8th day after administration relative to the total score on the first day of treatment, for dogs that received the test reagent and antiflatulent in each group in Table 1. FIG. 1 is a graph showing the number of days until complete recovery in dogs administered with test reagents and antiflatulents in each group in Table 1. FIG. 1 is a graph showing the clinical grade of the total score on the day of the start of treatment and the total score on the 8th day after administration for dogs that received the test reagent and the antiflatulent in each group in Table 1. FIG. 1 is a graph showing changes in the total score on the day of the start of treatment and the total score on the 8th day after administration for dogs in groups S and B in Table 1 that received a test drug and an antiflatulent agent. 2 is a graph showing total scores on the day of treatment initiation and 4 days after administration for dogs in group S of Table 1 that received the test reagent and the antiflatulent agent.

The supplement of the present invention will be described with reference to the drawings.

The supplement of the present invention is a symbiotic supplement characterized by using spore-bearing lactic acid bacteria and butyric acid bacteria as probiotics, and kestose, which is a nutrient source for beneficial bacteria such as bifidobacteria, as prebiotics. . _In addition, it is a supplement intended to improve various diseases such as skin diseases by blending vitamin B2 and vitamin E, which have antioxidant effects.

(spore-bearing lactic acid bacteria)
Spore-bearing lactic acid bacteria are lactic acid bacteria whose cells are protected by forming spores wrapped in a shell, unlike general lactic acid bacteria. Generally, lactic acid bacteria die at 70°C, but the spore-bearing lactic acid bacteria used in this supplement show almost no decrease in the number of bacteria even after heat treatment at 90°C for 30 minutes in physiological saline. It has a high survival rate even when heat-treated at , and exhibits high preservability even in a high-concentration environment of 20% salt and 50% sugar. Therefore, it is very stable both in the powder state and in the state of being added to food. Bacterial count can be maintained. It is also stable in tablets and edible oils.

By forming spores and protecting lactic acid bacteria with spores, even in strongly acidic (pH 2.0) artificial gastric juice, the survival rate is high during the normally assumed action time of gastric juice (2 hours). , can reach the intestinal tract as they go without dying on the way. Spore-bearing lactic acid bacteria are very robust as described above, but germinate in the intestinal tract to become active vegetative cells, propagate and settle. The lactic acid production rate is 90% or more, and the production rate is relatively slow, but because it continues to increase over a long period of time, the intestinal tract tends to be acidic, creating an environment where not only lactic acid bacteria but also bifidobacteria, which are indigenous bacteria, can easily increase. Become. Bacteriocins produced by lactic acid-producing bacteria suppress intestinal colonization of foreign pathogens and play a role in defense against infection other than the immune system. In addition, lactic acid produced by lactic acid-producing bacteria suppresses the growth of pathogenic bacteria that have entered the intestine and serves as an energy source for the intestinal epithelium. In order to effectively regulate the intestinal environment, the supplement of the present invention preferably contains 10 ⁴ to 10 ¹⁵ spore-bearing lactic acid bacteria per day.

(butyric acid bacteria)
Butyric acid bacteria produce butyric acid by decomposing oligosaccharides and dietary fiber during the growth process in the intestine. Butyric acid is a type of short-chain fatty acid and plays an important role in protecting the environment of the large intestine. Specifically, it is used as the main energy source for mucosal cells in the large intestine and has the function of stimulating the mucous membrane and promoting peristalsis of the intestinal tract. Butyric acid prevents invasion of foreign pathogens by promoting secretion of mucus in the intestinal tract and protecting the intestinal wall. In addition, butyric acid has the action of adjusting the absorption of water and sodium, and is thought to improve diarrhea, loose stools, or constipation by adjusting the amount of water in the intestine. Furthermore, butyric acid also has the effect of helping the proliferation of intestinal epithelial cells, and can regulate the intestinal environment.

Clostridium butyricum used as butyric acid bacteria in this supplement is an obligatory anaerobic spore-forming butyric acid bacterium. Since it is an anaerobic bacterium, it can proliferate even in the large intestine where the oxygen concentration is low, making it suitable for improving the large intestine environment. Because it is a spore-forming bacterium, it is protected by a highly durable shell called a spore, making it less susceptible to heat and acid. In addition, Miyairi bacteria is C. elegans known as a causative bacterium of necrotizing enteritis. It has antibacterial activity against toxigenic Clostridium spp. such as perfringens and C. difficile. This antibacterial activity is exerted by bacteriocins. In order to effectively regulate the intestinal environment, the supplement of the present invention preferably contains 10 ⁴ to 10 ¹⁵ butyric acid bacteria per daily intake.

(Kestose)
The kestose used in this supplement is a fructooligosaccharide, a trisaccharide having a structure in which one molecule of fructose is β-2,1-linked to the fructose residue of sucrose, and is a highly safe food material. Kestose exhibits a sweet taste similar to that of sugar, but has half the calories of sugar, is less hygroscopic than other prebiotics, and is easy to handle. Since kestose is more easily utilized by beneficial bacteria than other fructooligosaccharides, it can rapidly proliferate beneficial bacteria in the intestine. When kestose was administered and short-chain fatty acids in the intestinal components were analyzed, an increase in butyric acid was confirmed, indicating that kestose proliferates butyric acid bacteria. The supplement of the present invention preferably contains 100 to 3000 mg of kestose per day in order to effectively grow beneficial bacteria in the intestine.

₍ Vitamin B2)
Vitamin _B2 is a vitamin that promotes the metabolism of carbohydrates, lipids and proteins and plays an important role as a coenzyme for oxidoreductases involved in energy production in the body. In particular, it plays a role in regenerating cells such as skin and mucous membranes and metabolizing lipid peroxides that damage cells. Since vitamin B2 is water _- soluble and is excreted in urine even if taken in excess, there is no need to worry about overdose. The supplement of the present invention preferably contains 0.1 to 1 mg of vitamin B ₂ per day, in order to effectively promote the growth of pets and cell regeneration of skin and mucous membranes.

(Vitamin E)
Vitamin E has a strong antioxidant action, prevents oxidation of lipids in the body, suppresses aging due to oxidation of cell membranes, prevents arteriosclerosis and thrombosis, and lowers blood pressure. It is also said to promote blood circulation and promote skin metabolism. The supplement of the present invention preferably contains 0.5 to 5 mg of vitamin E per day in order to effectively prevent lipid oxidation in the pet's body.

EXAMPLES The present invention will be described below based on examples, but the content and scope of the present invention are not limited by these examples.

In this example, a dog visited a veterinary hospital complaining of diarrhea (loose stool and watery stool) was treated with test reagents commonly used for diarrhea treatment such as antidiarrheals, antibiotics and anthelmintics, and the supplement of the present invention. A demonstration experiment was conducted in which oral administration was performed, clinical symptoms were evaluated at the start of treatment and after administration by a veterinarian, and the results were entered in a questionnaire. The test dogs were all 20 dogs under the age of 7 years old, and the presence or absence of castration and contraception was not considered.

The supplement administered in this example contains the above-mentioned spore-bearing lactic acid bacteria, butyric acid bacteria, and kestose as raw material components for improving intestinal flora and promoting health, as well as improving various diseases such as skin diseases. Riboflamin (vitamin B ₂ ) and vitamin E, which have antioxidant properties, are blended as raw material components for achieving . Lacris-S (commercially available from Mitsubishi Chemical Foods Co., Ltd. Lacris is a registered trademark) is used as a spore-bearing lactic acid bacterium. Table 1 shows the amount and proportion of each raw material in one tablet (300 mg) of the supplement, and Table 2 shows the main nutritional components.

(Example group, control group, and administration method)
As an example group, in addition to administering an antidiarrheal drug and, if necessary, an antibiotic or an anthelmintic, a "supplement group (S group)" was set in which this supplement was administered as an intestinal regulator, and as a control group, an antidiarrheal drug and In addition to administering antibiotics and anthelmintic drugs as needed in the "no antidiarrheal agent group (N group)", in addition to administering antidiarrheals and antibiotics and anthelmintic drugs as needed, Kyoritsu Pharmaceutical Co., Ltd. Two groups of "Bioim Buster group (group B)" were set to administer the commercially available Biome Buster (registered trademark) (Table 3). Incidentally, the test dogs were 10 dogs in the S group, 7 dogs in the B group, and 3 dogs in the N group.

The period of administration of the test agent was 3 days in all groups, and the period of administration of the antiflatulent agent in groups B and S was 7 days. The supplement may be administered in the form of a powder, 1 tablet twice a day for dogs weighing less than 5 kg, and 2 tablets once for 2 days for dogs weighing 5-10 kg. Anthelmintics were administered when gastrointestinal parasites were observed, and symptomatic treatments such as antibiotics, antiemetics, and fluids were administered as needed.

(Evaluation method)
Evaluation of clinical symptoms by a veterinarian was performed on the first day of treatment (before dosing), 4 days and 8 days after dosing. Evaluation items are "diarrhea state", "frequency of diarrhea", "degree of appetite", "activity", and "abdominal pain". evaluated (Table 4). Based on the total score calculated as the sum of the scores of all evaluation items, the clinical grade is classified as "complete recovery (score 0)", "mild (score 1-5)", "moderate (score 6-10)", " It was classified into 4 levels of severity (score 11-15).

(Evaluation results)
FIG. 1 shows the improvement rate (mean value) of the total score (Post total score) on the 8th day after administration relative to the total score (Pre total score) on the day of treatment start for dogs that received administration of each group. . Improvement rate (%)=(Pre total score−Post total score)/Pre total score×100. In the control group, there were dogs that did not completely recover on the 8th day after administration, and the improvement rate was 85.7% in group B and 66.7% in group N, whereas the example group ( In Group S), all 10 cows were completely cured on day 8 after administration (improvement value: 100%), and there was a tendency for the administration of the supplement of the present invention to accelerate the improvement.

FIG. 2 shows the number of days (mean value) until complete cure for dogs administered in each group. Group S, to which the supplement of the present invention was administered, tended to shorten the number of days until complete recovery compared to the control groups (B group, N group).

FIG. 3 shows changes in clinical grades of Pre total score and Post total score for dogs that received administration of each group. In the example group (group S) administered with the supplement of the present invention, even severe cases could be completely cured, but in the control groups (groups B and N), complete cure was not achieved or some cases recurred.

FIG. 4 shows the change values (mean values) of the Pre total score and the Post total score for the dogs that received the Example group (S group) and the Control group (B group). The S group (4.5) significantly reduced the total score compared to the B group (1.6), and the difference was significant (p<0.05). As shown in FIG. 5, dogs that received the Example group (S group) had a significantly lower overall score from the Pre total score (4.5) to 0.2 on day 4 after administration (p<0 .01).

(Specific case)
In a case of a Welsh Corgi (6-year-old female) diagnosed with acute colitis, the evaluation results at the first visit were: condition of diarrhea "watery stool (mixed with fresh blood)", frequency of diarrhea "severe/more than 5 times a day" , appetite "not eating at all", activity "moderately decreased", and an antidiarrheal drug (Dearbuster/Kyoritsu Seiyaku Co., Ltd.), an antibiotic (amoxicillin) and the supplement of the present invention were administered. As a result, four days after the administration, the condition of diarrhea was "normal", the frequency of diarrhea was "normal", the appetite was "normal", and the activity was "normal".

According to the evaluation results of the above examples, the combined treatment with the supplement of the present invention showed a better improvement rate than the combined treatment with no antiflatulent agent and with Dearbuster. can be treated with It is also believed to be effective against severe diarrhea. In the above examples, the drug was administered to dogs (pet animals), but it may be administered to other animals, or may be ingested by humans. Also, the supplement of the present invention may be incorporated into pet food. In addition, various modifications can be made without changing the gist of the present invention.

Claims (3)

A supplement characterized by containing spore-bearing lactic acid bacteria, butyric acid bacteria, and kestose and regulating intestinal flora. _2. The supplement according to claim 1, which contains vitamin B2 and vitamin E. 3. Pet food, characterized in that it contains the supplement according to claim 1 or 2.

Images